PathoGenetix Raises $4M in First Close of Series B | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – PathoGenetix, formerly called US Genomics, announced today the first closing of its Series B financing round, raising $4 million.

The Woburn, Mass.-based company added that it has received $9.5 million in commitments from investors for the round.

The funds will be used to complete development of PathoGenetix's first commercial systems for identifying pathogens in complex biological samples using its Genome Sequence Scanning technology.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: cell-free DNA from tumors is shorter than DNA from healthy cells, type 2 diabetes-related loci, and more.

Genetic analysis confirms that blood found on leaves collected near Marche-les-Dames some 80 years ago belongs to King Albert I of Belgium.

Researchers in the US begin to seek participants for the 1 million-person precision medicine cohort, the New York Times reports.

A new report indicates that women are underrepresented among US patent holders.